Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 2/3018% above fair value
$10.99−0.21 (-1.87%)
Close on Nov 13, 2026Market cap $320.09MP/E –Yield –
Enanta Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Enanta Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$53.82M. For fiscal 2025 it was -$80.76M. The highest annual figure on record is $124.79M in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$80.76M | – |
| FY2024 | Sep 30, 2024 | -$119.36M | – |
| FY2023 | Sep 30, 2023 | -$134.84M | – |
| FY2022 | Sep 30, 2022 | -$120.87M | – |
| FY2021 | Sep 30, 2021 | -$106.24M | – |
| FY2020 | Sep 30, 2020 | -$38.00M | -195.0% |
| FY2019 | Sep 30, 2019 | $40.00M | -56.0% |
| FY2018 | Sep 30, 2018 | $90.85M | +239.6% |
| FY2017 | Sep 30, 2017 | $26.75M | -17.7% |
| FY2016 | Sep 30, 2016 | $32.50M | -74.0% |
| FY2015 | Sep 30, 2015 | $124.79M | +545.3% |
| FY2014 | Sep 30, 2014 | $19.34M | +109.0% |
| FY2013 | Sep 30, 2013 | $9.25M | -56.9% |
| FY2012 | Sep 30, 2012 | $21.46M | -16.8% |
| FY2011 | Sep 30, 2011 | $25.80M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$16.05M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$10.64M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$10.02M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$17.10M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$22.65M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$29.38M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$23.59M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$32.15M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$34.24M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$30.36M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$36.06M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$38.91M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$29.50M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$26.39M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$31.82M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$33.03M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$29.63M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$32.92M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$33.02M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$28.87M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$11.43M | -183.0% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$18.87M | -357.8% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$21.94M | -572.8% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$10.96M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $13.78M | -51.7% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $7.32M | -79.1% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $4.64M | -80.1% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$502.00K | -102.9% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $28.54M | +90.7% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $35.11M | -36.0% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $23.30M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $17.47M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $14.96M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $54.86M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$12.58M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$8.98M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$6.55M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$2.64M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$655.00K | – |
See a number that looks wrong?